Abstract:Yumei Ge, 1, &ast Xiaoyu Gou, 1, &ast Xiaoyan Dong, 1, 2 Yumeng Peng, 1, 3 Fangfang Yang 4 1 Department of Laboratory Medicine Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, People's Republic of China; 2 The Second Medical College, Zhejiang Chinese Medical University, Hangzhou, 310014, People's Republic of China; 3 Department of Clinical Laboratory Diagnostics, Bengbu Medical College, Bengbu, 233030, People's Republic of China; 4 Department of Clinical Laboratory, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, 621000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fangfang Yang, Department of Clinical Laboratory, The Third Hospital of Mianyang (Sichuan mental health center), Mianyang, Sichuan, 621000, People's Republic of China, Email Purpose: At present, there is no gold standard or unified standard for the diagnosis of neurosyphilis, and the rate of misdiagnosis is high. The diagnosis of neurosyphilis is still challenging. This study compared the clinical indicators between neurosyphilis and latent syphilis infection in the central nervous system. The purpose of this study was to provide evidence for the differential diagnosis and prognosis of patients with neurosyphilis and latent syphilis infection of the central nervous system. Methods: The clinical data of 59 patients with neurosyphilis and 30 patients with latent syphilis infection in the nervous system from 2008 to 2021 were analyzed. The cerebrospinal fluid and serum biochemical markers were evaluated for all patients. Results: CSF-nucleated cells, CSF-TRUST, CSF-totalprotein and CSF-IgG ( P 450 mg/L) or nucleated cells (> 5 cells/L) indicates the destruction of the blood-brain barrier and intracranial inflammatory reaction, which is helpful to the diagnosis of neurosyphilis. It plays an important role in the judgment of curative effect and prognosis of the disease as well. 5 Guidelines from different regions of the world indicate that the positive cerebrospinal fluid VDRL/RPR /TRUST can be used as the marker for the diagnosis of neurosyphilis. 6,7 Patients with cerebrospinal fluid VDRL positive and accompanied by neurological symptoms and signs, excluding blood contamination of cerebrospinal fluid, can be diagnosed with neurosyphilis. If the patient's serological test is positive, cerebrospinal fluid VDRL is negative, but the patient's cerebrospinal fluid cell count or protein determination is abnormal, and accompanied by neurosyphilis symptoms and signs, the diagnosis of neurosyphilis should be considered. Studies have shown that CSF-TRUST has the same diagnostic ability as CSF-VRDL, -Abstract Truncated-

Serum Ubiquitin C-Terminal Hydrolase-L1, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain Are Good Entry Points and Biomarker Candidates for Neurosyphilis Diagnosis among Patients Without Human Immunodeficiency Virus to Avoid Lumbar Puncture

Evaluation of Cerebrospinal Fluid Ubiquitin C-terminal Hydrolase-L1, Glial Fibrillary Acidic Protein, and Neurofilament Light Protein As Novel Markers for the Diagnosis of Neurosyphilis among HIV-negative Patients.

Clinical Characteristics, Diagnosis, and Predictors of Neurosyphilis Patients with Human Immunodeficiency Virus Co-Infection

Comparing Noninvasive Predictors of Neurosyphilis among Syphilis Patients with and Without HIV Co-Infection Based on the Real-World Diagnostic Criteria: A Single-Center, Retrospective Cohort Study in China.

Neutrophil-associated Proteins as Novel Biomarkers Elevated in Cerebrospinal Fluid of Neurosyphilis Patients

Assessing Cerebrospinal Fluid Abnormalities in Neurosyphilis Patients Without Human Immunodeficiency Virus Infection

Erratum to: Novel predictors of neurosyphilis among HIV-negative syphilis patients with neurological symptoms: an observational study

Serum TRSUT Titer ≥1: 16 Is a Predictor for Neurosyphilis Among HIV-Infected Patients With Concurrent Syphilis and No Neurological Symptoms.

Clinical Prediction and Diagnosis of Neurosyphilis in HIV-negative Patients: a Case-Control Study

Cxcl13, Cxcl10 and Cxcl8 As Potential Biomarkers for the Diagnosis of Neurosyphilis Patients

CXCL13 Chemokine As a Promising Biomarker to Diagnose Neurosyphilis in HIV-negative Patients

Serum TRSUT Titer ≥1

Macrophage Migration Inhibitory Factor As a Novel Cerebrospinal Fluid Marker for Neurosyphilis among HIV-negative Patients.

Increased CCL24 and CXCL7 Levels in the Cerebrospinal Fluid of Patients with Neurosyphilis

Large‐Scale Proteome Profiling Identifies Biomarkers Associated with Suspected Neurosyphilis Diagnosis

Predicting asymptomatic neurosyphilis using peripheral blood indicators

Cerebrospinal Fluid Changes and Clinical Features of Neurosyphilis Compared with Latent Syphilis Infection in the Central Nervous System: A Cross-Sectional Study

Exosomal Microrna Profiles from Serum and Cerebrospinal Fluid in Neurosyphilis.

Clinical Features of and Factors Correlated with Neurosyphilis in HIV/Syphilis Co-Infected Patients Based on Stage of Syphilis

Analysis of Treponema Pallidum DNA and CXCL13 in Cerebrospinal Fluid in HIV-Negative Syphilis Patients

Clinical and Laboratory Data-Based Nomograms for Neurosyphilis Diagnosis in Non-Hiv Syphilis Patients: a Cross-Sectional Study.